1. Sanyal AJ, Brunt EM, Kleiner DE, et al. Endpoints and clinical trial design for nonalcoholic steatohepatitis. Hepatology. 2011;54(1):344-53. https://doi.org/10.1002/hep.24376.
2. Golabi P, Paik JM, AlQahtani S, et al. Burden of non-alcoholic fatty liver disease in Asia, the Middle East and North Africa: Data from Global Burden of Disease 2009-2019. J Hepatol. 2021;https://doi.org/10.1016/j.jhep.2021.05.022.
3. Younossi Z, Anstee QM, Marietti M, et al. Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention. Nat Rev Gastroenterol Hepatol. 2018;15(1):11-20. https://doi.org/10.1038/nrgastro.2017.109.
4. Chalasani N, Younossi Z, Lavine JE, et al. The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases. Hepatology. 2018;67(1):328-357. https://doi.org/10.1002/hep.29367.
5. Golabi P, Rhea L, Henry L, et al. Hepatocellular carcinoma and non-alcoholic fatty liver disease. Hepatol Int. 2019;13(6):688-694. https://doi.org/10.1007/s12072-019-09995-8.
6. Younossi ZM, Stepanova M, Rafiq N, et al. Pathologic criteria for nonalcoholic steatohepatitis: interprotocol agreement and ability to predict liver-related mortality. Hepatology. 2011;53(6):1874-82. https://doi.org/10.1002/hep.24268.
7. Angulo P, Kleiner DE, Dam-Larsen S, et al. Liver Fibrosis, but No Other Histologic Features, Is Associated With Long-term Outcomes of Patients With Nonalcoholic Fatty Liver Disease. Gastroenterology. 2015;149(2):389-97 e10. https://doi.org/10.1053/j.gastro.2015.04.043.
8. Wong RJ, Aguilar M, Cheung R, et al. Nonalcoholic steatohepatitis is the second leading etiology of liver disease among adults awaiting liver transplantation in the United States. Gastroenterology. 2015;148(3):547-55. https://doi.org/10.1053/j.gastro.2014.11.039.
9. Li J, Zou B, Yeo YH, et al. Prevalence, incidence, and outcome of non-alcoholic fatty liver disease in Asia, 1999-2019: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2019;4(5):389-398. https://doi.org/10.1016/S2468-1253(19)30039-1.
10. Paik JM, Golabi P, Younossi Y, et al. Changes in the Global Burden of Chronic Liver Diseases From 2012 to 2017: The Growing Impact of NAFLD. Hepatology. 2020;72(5):1605-1616. https://doi.org/10.1002/hep.31173.
11. Sanai FM, Al Khathlan A, Al Fadhli A, et al. Clinical and economic burden of nonalcoholic steatohepatitis in Saudi Arabia, United Arab Emirates and Kuwait. Hepatol Int. 2021;https://doi.org/10.1007/s12072-021-10182-x.
12. Flemming JA, Djerboua M, Groome PA, et al. NAFLD and Alcohol-Associated Liver Disease Will Be Responsible for Almost All New Diagnoses of Cirrhosis in Canada by 2040. Hepatology. 2021;https://doi.org/10.1002/hep.32032.
13. Morgan A, Hartmanis S, Tsochatzis E, et al. Disease burden and economic impact of diagnosed non-alcoholic steatohepatitis (NASH) in the United Kingdom (UK) in 2018. Eur J Health Econ. 2021;22(4):505-518. https://doi.org/10.1007/s10198-020-01256-y.
14. Chan WK, Tan AT, Vethakkan SR, et al. Non-alcoholic fatty liver disease in diabetics--prevalence and predictive factors in a multiracial hospital clinic population in Malaysia. J Gastroenterol Hepatol. 2013;28(8):1375-83. https://doi.org/10.1111/jgh.12204.
15. Hodson L, Gunn PJ. The regulation of hepatic fatty acid synthesis and partitioning: the effect of nutritional state. Nat Rev Endocrinol. 2019;15(12):689-700. https://doi.org/10.1038/s41574-019-0256-9.
16. Vernon G, Baranova A, Younossi ZM. Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults. Aliment Pharmacol Ther. 2011;34(3):274-85. https://doi.org/10.1111/j.1365-2036.2011.04724.x.
17. Portillo Sanchez P, Bril F, Maximos M, et al. High Prevalence of Nonalcoholic Fatty Liver Disease in Patients with Type 2 Diabetes Mellitus and Normal Plasma Aminotransferase Levels. J Clin Endocrinol Metab. 2014;100(5)https://doi.org/10.1210/jc.2014-2739.
18. Alexander M, Loomis AK, van der Lei J, et al. Non-alcoholic fatty liver disease and risk of incident acute myocardial infarction and stroke: findings from matched cohort study of 18 million European adults. BMJ. 2019;367:l5367. https://doi.org/10.1136/bmj.l5367.
19. Diseases GBD, Injuries C. Global burden of 369 diseases and injuries in 204 countries and territories, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet. 2020;396(10258):1204-1222. https://doi.org/10.1016/S0140-6736(20)30925-9.
20. Fan J, Liu Z, Mao X, et al. Global trends in the incidence and mortality of esophageal cancer from 1990 to 2017. Cancer Med. 2020;9(18):6875-6887. https://doi.org/10.1002/cam4.3338.
21. Collaborators GBDN. Global, regional, and national burden of neurological disorders, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol. 2019;18(5):459-480. https://doi.org/10.1016/S1474-4422(18)30499-X.
22. Ferguson D, Finck BN. Emerging therapeutic approaches for the treatment of NAFLD and type 2 diabetes mellitus. Nat Rev Endocrinol. 2021;17(8):484-495. https://doi.org/10.1038/s41574-021-00507-z.
23. Allen AM, Therneau TM, Larson JJ, et al. Nonalcoholic fatty liver disease incidence and impact on metabolic burden and death: A 20 year-community study. Hepatology. 2018;67(5):1726-1736. https://doi.org/10.1002/hep.29546.
24. Sanai FM, Abaalkhail F, Hasan F, et al. Management of nonalcoholic fatty liver disease in the Middle East. World J Gastroenterol. 2020;26(25):3528-3541. https://doi.org/10.3748/wjg.v26.i25.3528.
25. Williams CD, Stengel J, Asike MI, et al. Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: a prospective study. Gastroenterology. 2011;140(1):124-31. https://doi.org/10.1053/j.gastro.2010.09.038.
26. Soresi M, Noto D, Cefalu AB, et al. Nonalcoholic fatty liver and metabolic syndrome in Italy: results from a multicentric study of the Italian Arteriosclerosis society. Acta Diabetol. 2013;50(2):241-9. https://doi.org/10.1007/s00592-012-0406-1.
27. Zois CD, Baltayiannis GH, Bekiari A, et al. Steatosis and steatohepatitis in postmortem material from Northwestern Greece. World J Gastroenterol. 2010;16(31):3944-9. https://doi.org/10.3748/wjg.v16.i31.3944.
28. Alazawi W, Mathur R, Abeysekera K, et al. Ethnicity and the diagnosis gap in liver disease: a population-based study. Br J Gen Pract. 2014;64(628):e694-702. https://doi.org/10.3399/bjgp14X682273.
29. Fan JG, Kim SU, Wong VW. New trends on obesity and NAFLD in Asia. J Hepatol. 2017;67(4):862-873. https://doi.org/10.1016/j.jhep.2017.06.003.
30. Juanola O, Martinez-Lopez S, Frances R, et al. Non-Alcoholic Fatty Liver Disease: Metabolic, Genetic, Epigenetic and Environmental Risk Factors. Int J Environ Res Public Health. 2021;18(10)https://doi.org/10.3390/ijerph18105227.
31. Eslam M, Newsome PN, Sarin SK, et al. A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement. J Hepatol. 2020;73(1):202-209. https://doi.org/10.1016/j.jhep.2020.03.039.
32. Eslam M, Sanyal AJ, George J, et al. MAFLD: A Consensus-Driven Proposed Nomenclature for Metabolic Associated Fatty Liver Disease. Gastroenterology. 2020;158(7):1999-2014 e1. https://doi.org/10.1053/j.gastro.2019.11.312.
33. Mishra A, Younossi ZM. Epidemiology and Natural History of Non-alcoholic Fatty Liver Disease. J Clin Exp Hepatol. 2012;2(2):135-44. https://doi.org/10.1016/S0973-6883(12)60102-9.
34. Leite NC, Villela-Nogueira CA, Pannain VL, et al. Histopathological stages of nonalcoholic fatty liver disease in type 2 diabetes: prevalences and correlated factors. Liver Int. 2011;31(5):700-6. https://doi.org/10.1111/j.1478-3231.2011.02482.x.
35. Tilg H, Moschen AR, Roden M. NAFLD and diabetes mellitus. Nat Rev Gastroenterol Hepatol. 2017;14(1):32-42. https://doi.org/10.1038/nrgastro.2016.147.
36. Population GBD, Fertility C. Population and fertility by age and sex for 195 countries and territories, 1950-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2018;392(10159):1995-2051. https://doi.org/10.1016/S0140-6736(18)32278-5.
37. Delli Bovi AP, Marciano F, Mandato C, et al. Oxidative Stress in Non-alcoholic Fatty Liver Disease. An Updated Mini Review. Front Med (Lausanne). 2021;8:595371. https://doi.org/10.3389/fmed.2021.595371.
38. Kleiner DE, Makhlouf HR. Histology of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis in Adults and Children. Clin Liver Dis. 2016;20(2):293-312. https://doi.org/10.1016/j.cld.2015.10.011.
39. Argo CK, Caldwell SH. Epidemiology and natural history of non-alcoholic steatohepatitis. Clin Liver Dis. 2009;13(4):511-31. https://doi.org/10.1016/j.cld.2009.07.005.
40. Starley BQ, Calcagno CJ, Harrison SA. Nonalcoholic fatty liver disease and hepatocellular carcinoma: a weighty connection. Hepatology. 2010;51(5):1820-32. https://doi.org/10.1002/hep.23594.
41. Ratziu V, Bellentani S, Cortez-Pinto H, et al. A position statement on NAFLD/NASH based on the EASL 2009 special conference. J Hepatol. 2010;53(2):372-84. https://doi.org/10.1016/j.jhep.2010.04.008.
42. Zhang T, Xu J, Ye L, et al. Age, Gender and Geographic Differences in Global Health Burden of Cirrhosis and Liver Cancer due to Nonalcoholic Steatohepatitis. J Cancer. 2021;12(10):2855-2865. https://doi.org/10.7150/jca.52282.
43. Kim D, Adejumo AC, Yoo ER, et al. Trends in Mortality From Extrahepatic Complications in Patients With Chronic Liver Disease, From 2007 Through 2017. Gastroenterology. 2019;157(4):1055-1066 e11. https://doi.org/10.1053/j.gastro.2019.06.026.
44. Stepanova M, Younossi ZM. Independent association between nonalcoholic fatty liver disease and cardiovascular disease in the US population. Clin Gastroenterol Hepatol. 2012;10(6):646-50. https://doi.org/10.1016/j.cgh.2011.12.039.
45. Marchesini G, Bugianesi E, Forlani G, et al. Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology. 2003;37(4):917-23. https://doi.org/10.1053/jhep.2003.50161.